Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hangzhou Tigermed Consulting Co., Ltd (300347.SZ)
Hangzhou, TJ, CN
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.54% | -5.91% | -28.53% | -33.85% | -22.66% | -30.42% | -20.37% | -51.95% | -77.46% | +107.09% | +846.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Biotechnology: +1.6%+3.5% ★ Q1'26: +15.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+121.3% ★ Q1'26: -68.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.4% Q1'26: +14.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.9% ★ Q1'26: +11.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.0% ★ Q1'26: +2.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.1% ★ Q1'26: -6.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.80× ★ Q1'26: 1.71× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 6 EPS Ana. |
Dec 2027 15 Rev. Ana. 8 EPS Ana. |
Dec 2028 12 Rev. Ana. 9 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
957.00M
est: 903.00M (+6.0%)
|
1.17B
est: 1.16B (+1.4%)
|
1.69B
est: 1.71B (-1.1%)
|
2.30B
est: 2.29B (+0.6%)
|
2.80B
est: 2.89B (-3.1%)
|
3.19B
est: 3.27B (-2.5%)
|
4.77B
est.
|
5.21B
est: 7.10B (-26.6%)
|
7.09B
est: 7.03B (+0.8%)
|
7.38B
est: 7.03B (+5.0%)
|
6.60B
est: 6.75B (-2.1%)
|
6.83B
est: 6.95B (-1.6%)
|
7.70B
7.57B – 7.85B
+10.8% YoY
|
8.77B
8.23B – 9.93B
+14.0% YoY
|
10.05B
10.01B – 10.08B
+14.5% YoY
|
| EBITDA |
256.94M
est: 232.82M (+10.4%)
|
257.64M
est: 298.57M (-13.7%)
|
474.33M
est: 439.99M (+7.8%)
|
684.21M
est: 589.41M (+16.1%)
|
1.17B
est: 745.65M (+57.4%)
|
2.35B
est: 844.09M (+178.4%)
|
1.23B
est.
|
3.83B
est: 1.83B (+109.0%)
|
2.83B
est: 2.51B (+12.8%)
|
2.80B
est: 2.51B (+11.3%)
|
1.02B
est: 2.41B (-57.9%)
|
820.30M
est: 2.48B (-66.9%)
|
2.75B
2.71B – 2.80B
+10.8% YoY
|
3.13B
2.94B – 3.55B
+14.0% YoY
|
3.59B
3.58B – 3.60B
+14.5% YoY
|
| EBIT |
225.51M
est: 210.14M (+7.3%)
|
222.15M
est: 269.49M (-17.6%)
|
443.79M
est: 397.13M (+11.7%)
|
626.02M
est: 531.99M (+17.7%)
|
1.13B
est: 673.02M (+68.0%)
|
2.27B
est: 761.86M (+198.0%)
|
1.11B
est.
|
3.71B
est: 1.65B (+124.6%)
|
2.67B
est: 2.33B (+14.9%)
|
2.61B
est: 2.33B (+12.2%)
|
810.77M
est: 2.23B (-63.7%)
|
608.47M
est: 2.30B (-73.5%)
|
2.55B
2.51B – 2.60B
+10.8% YoY
|
2.90B
2.72B – 3.29B
+14.0% YoY
|
3.33B
3.31B – 3.34B
+14.5% YoY
|
| Net Income |
156.28M
est: 224.12M (-30.3%)
|
140.65M
est: 186.77M (-24.7%)
|
301.01M
est: 344.80M (-12.7%)
|
472.18M
est: 541.25M (-12.8%)
|
841.63M
est: 935.49M (-10.0%)
|
1.75B
est: 1.63B (+7.7%)
|
2.57B
est.
|
2.87B
est: 2.55B (+12.8%)
|
2.01B
est: 1.13B (+77.7%)
|
2.02B
est: 1.13B (+79.3%)
|
405.14M
est: 1.06B (-61.7%)
|
887.89M
est: 1.09B (-18.7%)
|
1.03B
915.28M – 1.07B
-5.5% YoY
|
1.47B
878.88M – 1.50B
+42.4% YoY
|
1.73B
1.38B – 1.97B
+18.0% YoY
|
| SGA |
200.82M
est: 117.21M (+71.3%)
|
264.24M
est: 150.31M (+75.8%)
|
276.23M
est: 221.50M (+24.7%)
|
368.65M
est: 296.72M (+24.2%)
|
430.71M
est: 375.38M (+14.7%)
|
487.22M
est: 424.93M (+14.7%)
|
619.59M
est.
|
676.88M
est: 921.72M (-26.6%)
|
780.02M
est: 895.74M (-12.9%)
|
837.52M
est: 895.74M (-6.5%)
|
944.45M
est: 859.56M (+9.9%)
|
960.56M
est: 884.80M (+8.6%)
|
980.37M
964.68M – 999.49M
+10.8% YoY
|
1.12B
1.05B – 1.27B
+14.0% YoY
|
1.28B
1.28B – 1.28B
+14.5% YoY
|
| EPS |
0.24
est: 0.26 (-7.7%)
|
0.20
est: 0.22 (-7.7%)
|
0.41
est: 0.40 (+2.5%)
|
0.63
est: 0.63 (+0.3%)
|
1.13
est: 1.09 (+4.1%)
|
2.20
est: 1.89 (+16.7%)
|
2.98
est.
|
3.31
est: 2.78 (+19.2%)
|
2.32
est: 1.30 (+77.9%)
|
2.34
est: 1.30 (+79.5%)
|
0.47
est: 1.21 (-61.1%)
|
1.04
est: 1.25 (-16.6%)
|
1.13
1.07 – 1.25
-9.3% YoY
|
1.51
1.03 – 1.76
+33.6% YoY
|
1.97
1.62 – 2.30
+30.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.57% | 1.26M | 0.68% |
| 2 | KraneShares MSCI All China Health Care Index ETF KURE | 0.41% | 330.0K | 0.79% |
| 3 | VanEck ChiNext ETF CNXT | 0.37% | 450.7K | 0.65% |
| 4 | JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L | 0.16% | 35.5K | 0.40% |
| 5 | Amundi MSCI EM Asia SRI Climate Paris Aligned UCITS ETF DR (D) SADA.L | 0.11% | 239.0K | 0.25% |
| 6 | Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (D) MSDU.L | 0.09% | 2.72M | 0.25% |
| 7 | Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C) MSRU.L | 0.09% | 2.72M | 0.25% |
| 8 | Samsung KODEX China CSI300 ETF 283580.KS | 0.09% | 180.5K | 0.12% |
| 9 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.09% | 14.0K | 0.65% |
| 10 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.06% | 44.6K | 0.55% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xiaoping Ye D.Phil EMBA | Co-Founder & Chairman | 3M | — |
| Zengyu Wen | Co-President, Executive VP, COO & Executive Director | 2M | male |
| Hao Wu | Co- President & Executive Director | 2M | male |
| Xiaochun Cao | Co-Founder, GM & Executive Director | 866.0K | — |
| Mo Shuang | Chief Compliance Officer | — | female |
| Chengcheng Yang | Chief Financial Officer | — | female |
| Xiao Li Shi | Vice President & Head of Data Resources Department | — | — |
| Xiao Ri Li | Secretary | — | female |
| Yun Jie Gong | Senior VP & Chief Quality Officer | — | — |
| Tianrong Ji | Chief Investment Officer | — | — |
| Guoyun Yu | Head of Accounting Department | — | male |
| Jiansong Yang | Senior Vice President & Chief Scientific Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300347.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
